Morningstar1mon
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell ...
Cure Today18d
FDA-Approved Calquence Combo Is First and Only of Its Kind in MCL
Calquence, a BTK inhibitor, is now approved for first-line treatment of MCL, offering a new therapeutic option for patients ineligible for stem cell transplantation. The ECHO trial showed significant ...
Hosted on MSN1mon
AstraZeneca lymphoma therapy Calquence gets expanded approval in the U.S.
The latest approval allows Calquence use with bendamustine and rituximab for adults with newly diagnosed mantle cell lymphoma who are not eligible to undergo hematopoietic stem cell ...
MedCity News1mon
FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer
Chemotherapy is the standard treatment, but relapse is common. Acalabrutinib, marketed under the brand name Calquence, is a small molecule designed to block Bruton’s tyrosine kinase (BTK), an ...
Cure Today11d
FDA Approval of Calquence Combo Brings Optimism in MCL
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...
Monthly Prescribing Reference1mon
Calquence Combo Therapy Approved for Previously Untreated Mantle Cell Lymphoma
Findings showed acalabrutinib with bendamustine and rituximab (BR) reduced the risk of disease progression or death by 27% compared with placebo plus BR. The Food and Drug Administration (FDA) has ...
pharmaphorum5d
AZ says Calquence is a safer drug than Imbruvica
AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL).
pharmaphorum1mon
Calquence approval another win for AstraZeneca in oncology
AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...
WebMD8d
FDA Approves New Drug Combination for Mantle Cell Lymphoma
Acalabrutinib, made by the drug company AstraZeneca and marketed under the brand name Calquence, works by blocking an enzyme called Bruton’s tyrosine kinase (BTK), which helps cancerous B cells ...
Healio5d
VIDEO: Results of AMPLIFY trial ‘biggest splash’ for front-line treatment of CLL
In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca ...
Pharmabiz1mon
AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma
AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...